Clinical trials: Refractory Classic Hodgkin Lymphoma
Relapsed/Refractory Classical Hodgkin's Lymphoma
Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
The study is to evaluate ORR, CR, PR DCR DOR PFS and safety of IBI308 in treatment of patients with Relapsed/Refractory Hodgkin's Lymphoma.
- Trial name
- ORIENT-1 (NCT03114683)
- Testing
- PD1
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Classical Hodgkin Lymphoma, Relapsed or Refractory Classical Hodgkin Lymphoma
B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes
The purpose of this study is to describe progression-free survival (PFS) in participants with relapsed or refractory classical Hodgkin lymphoma (RRHL), defined as the time from initiation of first treatment for RRHL to first…
- Trial name
- B-HOLISTIC (NCT03327571)
- Where
- South Korea
- Volunteers
- 1,770 people
- Sponsor
- Takeda
Classical Hodgkin Lymphoma
An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma
The study is to evaluate the efficacy of KL-A167 a in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano Classification
- Trial name
- NCT03580564
- Testing
- KL-A167
- Where
- China
- Volunteers
- 109 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
This is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or refractory CD30+ classical Hodgkin Lymphoma.
- Conditions
- Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric
- Trial name
- NCT04268706
- Testing
- CD30.CAR-T, Fludarabine, Bendamustine
- Where
- 5 sites in United States
- Volunteers
- 97 people
- Sponsor
- Tessa Therapeutics
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of gemcitabine, bendamustine, and nivolumab when given together and to see how well they work in treating patients with classic Hodgkin lymphoma that has come back or…
- Conditions
- Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Hodgkin Lymphoma
- Trial name
- NCT03739619
- Testing
- Bendamustine, Gemcitabine, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
This phase III trial compares chemotherapy versus an immune checkpoint inhibitor drug called pembrolizumab plus chemotherapy in treating patients with classical Hodgkin lymphoma that has come back (relapsed) or that does not…
- Trial name
- NCT05711628
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Bendamustine, Brentuximab Vedotin
- Sponsor
- National Cancer Institute (NCI)
Hodgkin's Lymphoma
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
Objectives: Primary objective: Phase-I: To determine the maximal tolerated dose (MTD) of panobinostat (LBH589) + Ifosfamide + Mesna, Carboplatin and Etoposide (ICE) combination Randomized Phase-II: To estimate the complete…
- Trial name
- NCT01169636
- Testing
- Panobinostat, Ifosfamide, Mesna
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphocyte-Rich Classical Hodgkin Lymphoma, Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma
Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this research study is to evaluate a new drug Pembrolizumab in combination with chemotherapy, for Relapsed/Refractory Hodgkin Lymphoma.
- Conditions
- Lymphocyte-Rich Classical Hodgkin Lymphoma, Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma, Recurrent Mixed Cellularity Classical Hodgkin Lymphoma, Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma
- Trial name
- NCT03077828
- Testing
- Carboplatin, Etoposide, Ifosfamide
- Where
- 6 sites in United States
- Volunteers
- 43 people
- Sponsor
- Northwestern University
Relapsed Classic Hodgkin Lymphoma
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment…
- Trial name
- NCT04561206
- Testing
- Brentuximab Vedotin, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Classical Hodgkin Lymphoma
Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
This phase II trial studies how well ibrutinib and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back or has not responded to treatment.
- Trial name
- NCT02940301
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Hodgkin Lymphoma
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
- Trial name
- NCT05180097
- Testing
- Gemcitabine, Dexamethasone, Cisplatin
- Where
- 18 sites in Australia, Canada
- Volunteers
- 84 people
- Sponsor
- Canadian Cancer Trials Group
Leukemia, Acute Myeloid, Myelodysplastic Syndromes
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment.
- Conditions
- Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell
- Trial name
- NCT05362773
- Testing
- MGD024
- Where
- 7 sites in United States
- Volunteers
- 130 people
- Sponsor
- MacroGenics
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.
This phase II trial studies how well combination chemotherapy with or without bortezomib works in treating patients with classical Hodgkin lymphoma that has come back or does not respond to prior treatment.
- Trial name
- NCT00967369
- Testing
- Bortezomib, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Malignant Solid Neoplasm, Anal Carcinoma
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus (HIV) associated classical Hodgkin lymphoma that has returned after a period…
- Conditions
- Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma
- Trial name
- NCT02408861
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- 34 sites in United States, Australia
- Volunteers
- 79 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin Lymphoma
Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma
Prolgolimab is an anti-PD-1 inhibitor that has previously been shown to be effective and safe for the treatment of patients with melanoma.
- Trial name
- Prolgo-HL (NCT05757466)
- Testing
- Prolgolimab, Combination with prolgolimab and bendamustine
- Where
- 2 sites in Russia
- Volunteers
- 30 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Classical Hodgkin Lymphoma
Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma
The aim of this trial is to develop an effective and well-tolerated regimen for treatment of r/r cHL by introducing the anti-PD-1 antibody pembrolizumab and adding it to well-established chemotherapy regimens (ICE, DHAP).
- Trial name
- Pembro-CORE (NCT04838652)
- Testing
- Pembrolizumab plus Chemotherapy (ICE or DHAP)
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- University of Cologne
Classic Hodgkin's Lymphoma, Recurrent Classic Hodgkin Lymphoma
GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)
The primary objective of this study is to evaluate the efficacy of GLS-010 in participants with relapsed or refractory classical Hodgkin lymphoma (R/R cHL), as measured by Progression-free Survival (PFS) as assessed by IRRC
- Conditions
- Classic Hodgkin's Lymphoma, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
- Trial name
- NCT05518318
- Testing
- GLS-010, Chemotherapy of Investigator's choice
- Volunteers
- 60 people
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma.
- Trial name
- NCT05451810
- Testing
- Epcoritamab
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 184 people
- Sponsor
- Genmab
Recurrent/Refractory Classical Hodgkin's Lymphoma
Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma
This study is a single arm, open, multi center phase II exploratory study. To evaluate the efficacy and safety of AK105 combined with androtinib hydrochloride capsule in patients with relapsed/refractory classical Hodgkin's…
- Trial name
- NCT05683704
- Testing
- AK105，Anrotinib hydrochloride
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hodgkin Lymphoma, Adult, Relapse
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
Young patients with relapsed or refractory classic Hodgkin's lymphoma will be treated with PD-1 inhibitor combined with decitabine as second-line salvage treatment for four cycles.
- Conditions
- Hodgkin Lymphoma, Adult, Relapse, Refractory Hodgkin Lymphoma
- Trial name
- NCT05137886
- Testing
- PD-1 inhibitor
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China